Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients

Table 5 Second stage time-dependent multivariate Cox model analysis of cytokine-induced killer cells immunotherapy at different frequencies and prognosis of patients^1,2 (n = 56)

Variables3	β	sβ	Wald-χ2	P-value	HR	95% CI
Number of CIK infusion	0.089	0.280	0.102	0.750	1.09	0.63-1.89
Sex	0.676	0.619	1.191	0.275	1.97	0.58-6.62
Age	-0.318	0.442	0.518	0.472	0.73	0.31-1.73
Tumor stages	-0.471	0.341	1.909	0.167	0.62	0.32-1.22
Relapse (yes or no)	2.203	0.558	15.582	< 0.0001	9.05	3.03-27.02

¹This model only involving the patients with a survival time longer than 36 mo. The survival rate of each patient was similar;

²Pearson correlation test between Schoenfeld residual of cytokine-induced killer (CIK) cells immunotherapy frequency and survival time (r = 0.307, F = 1.98, P = 0.176);

³Variable value definition in the Cox model (frequency of CIK cells immunotherapy: 0 = 0 time, 1 = 1-10 times, 2 = 11-25 times, 3 = more than 25 times; Sex: 1 = man, 2 = woman), age (0 = ≤ 45 yr, 1 = about 60 yr, 2 = over 60 yr), tumor stage (0 = stage I, 1 = stage II, 2 = stage III, 3 = stage IV), relapse (1 = yes, 0 = no). HR: Hazard risk; 95% CI: 95% confidence interval.